Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 31 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
Patents for A61P 31 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics (179,784)
10/2009
10/27/2009US7608284 Active enamel matrix substance, such as an amelogenin, a processed amelogenin product, or a metabolite can be used in treating conditions in a mammal which present an imbalance in its native immune resposne to external or internal stimuli
10/27/2009US7608276 vaccines, immunogenic compositions; diagnostics, enzymatic studies and targets for antibiotics; for treating Staphylococcus aureus infection
10/27/2009US7608274 Therapeutic processes and useful compositions therefor
10/27/2009US7608271 Modified human immunodeficiency virus anti-fusogenic GP41 peptides comprising a maleimide-containing group
10/27/2009US7608255 Replication-competent anti-cancer vectors
10/27/2009US7608253 end-capped polyethylene glycol carbamate derivatives useful as water-soluble pro-drugs; controll hydrolytic degradation of hydrogels; conjugate polymer drug for controlled release
10/27/2009US7608245 Transmission and, or amplification of signal ; oral or enteric administering; dissolving; absorption by small inteestines; peptide yy; obesity therapy
10/27/2009CA2536886C Crystal of 1-methyl carbapenem compound
10/27/2009CA2477019C Use of total coumarins of cnidium fruit in preparing medicaments for treating psoriasis
10/27/2009CA2476884C Macrolides with antibacterial activity
10/27/2009CA2466724C Benzamide and heteroarylamide as p2x7 receptor antagonists
10/27/2009CA2415966C Tetrahydro-heterocycloazepinyl pyrimidine derivatives
10/27/2009CA2410488C Methods of treating hepatitis delta virus infection with .beta.-l-2' deoxy-nucleosides
10/27/2009CA2404514C Novel substance having physiological property, method for producing the same and uses thereof
10/27/2009CA2372085C L-ribo-lna analogues
10/27/2009CA2342582C A method of inhibiting formation of infectious herpes virus particles
10/27/2009CA2341434C Pyrrolobenzodiazepine compounds
10/27/2009CA2338141C Polymer complexes of glucuronoglucanes
10/27/2009CA2328904C Novel (poly)peptides which represent the epitopes of the human herpesvirus type 8
10/27/2009CA2318694C Antivirals
10/27/2009CA2146145C Immunogenic meningococcal lps and outer membrane vesicles and vaccine therefrom
10/25/2009CA2629979A1 Novel resveratrol compositions
10/22/2009WO2009129525A2 Antifungal and anti-cariogenic cellobio-oligosaccharides produced by dextransucrase
10/22/2009WO2009129336A2 Penetrating carrier, antifungal composition using the same and method for treatment of dermatophyte infections
10/22/2009WO2009129305A2 Prodrugs of neuraminidase inhibitors
10/22/2009WO2009129164A1 Pharmaceutical combinations of tfpi-fragments and an antibiotic
10/22/2009WO2009129120A2 Nucleoside derivatives for treatment of caliciviridae infections, including norovirus infections
10/22/2009WO2009129109A1 Hepatitis c virus inhibitors
10/22/2009WO2009129094A2 Compositions containing antiviral compounds and methods of using the same
10/22/2009WO2009128964A2 Ensemble-based virtual screening reveals novel antiviral compounds for avian influenza neuraminidase
10/22/2009WO2009128963A2 Cross-neutralizing human monoclonal antibodies to sars-cov and methods of use thereof
10/22/2009WO2009128947A1 Piperazine derivatives
10/22/2009WO2009128523A1 Immunostimulating agent
10/22/2009WO2009128520A1 Heterocyclic compound having inhibitory activity on p13k
10/22/2009WO2009128489A1 Tablet containing vancomycin hydrochloride
10/22/2009WO2009128076A2 Methods of generating and using procollagen
10/22/2009WO2009128019A1 Tricyclic antibiotics
10/22/2009WO2009127996A1 Novel crystalline form of lamivudine
10/22/2009WO2009127924A1 Compositions and devices for antisepsis and anticoagulation
10/22/2009WO2009127825A1 Topical combinations comprising an antimycotic agent and an antiviral agent
10/22/2009WO2009127684A1 Vaccine for protection against lawsonia intracellularis, mycoplasma hyopneumoniae and porcine circo virus
10/22/2009WO2009127623A1 Crystalline (6r,7r)-7-{2-(5-amino-[1,2,4]thiadiazol-3-yl)-2-[(z)-trityloxyimino]-acetylamino}-3-[(r)-1'-tert-butoxycarbonyl-2-oxo-[1,3']bipyrrolidinyl-(3e)-ylidenemethyl]-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid benzhydryl ester; its manufacture and use
10/22/2009WO2009127519A1 Compositions comprising antibodies or antibody fragments
10/22/2009WO2009127060A1 Novel lipid formulations for nucleic acid delivery
10/22/2009WO2009099777A3 Chimeric hiv fusion proteins as vaccines
10/22/2009WO2009084975A8 Composition exhibiting high osmotic antimicrobial, anti-inflammatory and regeneration activity
10/22/2009WO2009084974A8 1,3-dialkyl-benzimidazole halogenides exhibiting regeneration, anti-inflammatory and antimicrobial activity
10/22/2009WO2009082819A8 Novel lupane derivatives
10/22/2009WO2009046827A3 Use of growth hormone-releasing factor and/or mage-3 antigen (271-279) as therapeutic agents
10/22/2009WO2009043518A3 Use of a combination of cart peptides as a therapeutic agent
10/22/2009WO2009040050A3 Use of calcitonin as anti-angiogenic agent
10/22/2009WO2009040048A3 Use of the c-reactive peptide as a therapeutic agent
10/22/2009WO2009040036A3 Use of a galanin peptide as a therapeutic agent
10/22/2009WO2009039982A3 Use of gip alone or in combination with dynorphin b as a therapeutic agent
10/22/2009WO2009039972A3 Use of muramyl dipeptide (mdp) as a therapeutic agent
10/22/2009WO2009033810A3 Use of antioxidant peptide a (phckrm) and aplha-casein (90-96) as therapeutic agents in eg the treatment of hiv infection
10/22/2009WO2009004339A3 Modulation of reactive oxygen species in the treatment of respiratory infection
10/22/2009WO2008071961A8 2-quinolinone and 2-quinoxalinone- derivatives and their use as antibacterial agents
10/22/2009US20090264644 Novel Macrolide Compounds With Antibiotic and Antineoplastic Properties
10/22/2009US20090264642 Anhydrous crystal of bata-lactam compound and method for preparation thereof
10/22/2009US20090264624 Human cytokine receptor
10/22/2009US20090264506 Delivery of polynucleotide agents to the central nervous system
10/22/2009US20090264505 Methods and compositions for rnai mediated inhibition of gene expression in mammals
10/22/2009US20090264492 Pharmaceutical composition for the treatment of a fungal skin disorder and a method for the preparation thereof
10/22/2009US20090264424 Vanilloid receptor ligands and their use in treatments
10/22/2009US20090264381 Nucleic acid and corresponding protein entitled 151p3d4 useful in treatment and detection of cancer
10/22/2009US20090264380 6,11-bridged biaryl macrolides
10/22/2009US20090264362 Influenza virus inhibiting peptides
10/22/2009US20090264346 Macrocyclic peptides active against the hepatitis c virus
10/22/2009US20090263916 Antagonists of HMG1 for treating inflammatory conditions
10/22/2009US20090263883 Recombinant Parainfluenza Virus Expression Systems And Vaccines Comprising Heterologous Antigens Derived From Respiratory Syncytial Virus
10/22/2009US20090263514 Cold and flu tonic
10/22/2009US20090263495 Bacteriostatic or bacteriocidal compositions and methods
10/22/2009US20090263494 Manzanita
10/22/2009US20090263474 Methods for Treating Autoimmune Diseases in a Subject and In Vitro Diagnostic Assays
10/22/2009US20090263469 Biguanide-containing liposomes
10/22/2009US20090263438 Inhibition and dispersion of bacterial biofilms with imidazole-triazole derivatives
10/22/2009US20090263427 Vaccines for mycoplasma bovis and methods of use
10/22/2009US20090263419 Live attenuated bacterial vaccine
10/22/2009US20090263417 Multi-subtype FIV vaccines
10/22/2009US20090263413 Immunostimulatory oligonucleotides and use thereof in pharmaceuticals
10/22/2009US20090263404 Methods and Compositions for Using MHC Class II Invariant Chain Polypeptide as a Receptor for Macrophage Migration Inhibitory Factor
10/22/2009US20090263401 USES OF IL-174 ANTAGONISTS FOR INHIBITING A Th2 IMMUNE RESPONSE
10/22/2009US20090263386 Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency
10/22/2009US20090263352 Methods for treating viral infection using il-28 and il-29 cysteine mutants
10/22/2009CA2723262A1 Compositions and devices for antisepsis and anticoagulation
10/22/2009CA2722308A1 Nucleoside derivatives for treatment of caliciviridae infections, including norovirus infections
10/22/2009CA2721586A1 Compositions containing antiviral compounds and methods of using the same
10/22/2009CA2721507A1 Methods of generating and using procollagen
10/22/2009CA2721457A1 Topical combinations comprising an antimycotic agent and an antiviral agent
10/22/2009CA2721399A1 Substituted tetracycline compounds
10/22/2009CA2721333A1 Novel lipid formulations for nucleic acid delivery
10/22/2009CA2721203A1 Inhibitors of protein phosphatase-1 and uses thereof
10/22/2009CA2720672A1 Tricyclic antibiotics
10/22/2009CA2720210A1 Compositions comprising antibodies or antibody fragments
10/22/2009CA2718787A1 Vaccine for protection against lawsonia intracellularis, mycoplasma hyopneumoniae and porcine circo virus
10/21/2009EP2110381A1 Long lasting fusion peptide inhibitors of viral infection
10/21/2009EP2110137A1 Vaccine against neisseria infection
10/21/2009EP2110134A1 Cocoa extract compounds and methods for making and using the same
10/21/2009EP2109602A2 Tetracycline derivatives for the treatment of bacterial, viral and parasitic infections
1 ... 589 590 591 592 593 594 595 596 597 598 599 600 601 602 603 604 605 606 607 608 609 ... 1798